# Microscale Affinity Chromatography for Biointeraction Analysis: Strategies, Principles and Applications

**Authors:** David S. Hage, Nigar Sultana Pinky, B. K. Sajeeb, Md Masudur Rahman, Harshana Olupathage, Samiul Alim, Isaac Kyei, Zoe Zingler, Sanduni Heenkenda

PMC · DOI: 10.1002/jssc.70361 · Journal of Separation Science · 2026-02-08

## TL;DR

This review discusses microscale affinity chromatography as a tool for studying biological interactions and their applications in biochemical and biomedical research.

## Contribution

The paper provides a comprehensive review of strategies and principles of microscale affinity chromatography for biointeraction analysis.

## Key findings

- Microscale affinity chromatography is effective for characterizing biointeractions using immobilized binding agents.
- Various methods like zonal and frontal analysis are useful for studying interaction kinetics.
- µAC platforms offer versatile schemes for probing solution-phase and direct interactions.

## Abstract

The analysis of interactions between biological agents or with surrounding chemicals is important in many areas of modern biochemical, biomedical, and environmental research. Microscale platforms based on affinity chromatography have been shown to be a powerful set of tools for these studies. This approach makes use of an immobilized binding agent as a stationary phase in a microscale platform for either direct examination of the interactions of this agent with an applied target solute or as a secondary capture agent to probe a solution‐phase interaction. This review will examine the various platforms and strategies that have been used in microscale affinity chromatography, or µAC, to characterize and study biointeractions. The general principles of µAC and schemes based on this approach will be examined, along with applications of this technique. Examples of approaches that will be considered will include zonal and frontal analysis methods, as well as a variety of schemes by which µAC can be employed in kinetic studies. In each case, the theory and principles of these methods will be provided along with examples of their use in biointeraction studies.

## Full-text entities

- **Genes:** GAK (cyclin G associated kinase) [NCBI Gene 511296], ALB (albumin) [NCBI Gene 280717], ADRA1A (adrenoceptor alpha 1A) [NCBI Gene 282134], DHFR (dihydrofolate reductase) [NCBI Gene 508809], CASR (calcium sensing receptor) [NCBI Gene 281038] {aka BoPCaR1}, SHBG (sex hormone binding globulin) [NCBI Gene 404182], ADRB2 (adrenoceptor beta 2) [NCBI Gene 281605], KDR (kinase insert domain receptor) [NCBI Gene 407170] {aka VEGFR2, flk-1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, VDAC1 (voltage dependent anion channel 1) [NCBI Gene 282119], LOC781146 (lysozyme) [NCBI Gene 781146]
- **Diseases:** advanced glycation end-products (MESH:D003643), cancer (MESH:D009369)
- **Chemicals:** repaglinide (MESH:C072379), phenytoin (MESH:D010672), potassium phosphate (MESH:C013216), beta-cyclodextrin (MESH:C031215), 2,4-D (MESH:D015084), testosterone (MESH:D013739), carbohydrate (MESH:D002241), methylglyoxal (MESH:D011765), carbamazepine (MESH:D002220), diazepam (MESH:D003975), polymethacrylates (MESH:C030613), ATP (MESH:D000255), NADH (MESH:D009243), acetaminophen (MESH:D000082), L-fucose (MESH:D005643), serotonin (MESH:D012701), S-flurbiprofen (MESH:D005480), sodium nitrate (MESH:C031618), ephedrine hydrochloride (MESH:D004809), humic acid (MESH:D006812), warfarin (MESH:D014859), digitoxin (MESH:D004074), 5-(3-hydroxyphenyl)-5-phenylhydantoin (MESH:C027364), NADPH (MESH:D009249), water (MESH:D014867), salbutamol (MESH:D000420), rosmarinic acid (MESH:C041376), amitriptyline (MESH:D000639), NaCl (MESH:D012965), cathinones (MESH:C023665), retinoic acid (MESH:D014212), lidocaine (MESH:D008012), CA (MESH:D002118), tolbutamide (MESH:D014044), lipids (MESH:D008055), tamsulosin (MESH:D000077409), sulfonylureas (MESH:D013453), verapamil (MESH:D014700), glyoxal (MESH:D006037), quinidine (MESH:D011802), chlorpromazine (MESH:D002746), imipramine (MESH:D007099), L (MESH:D007930), sugar (MESH:D000073893), L-tryptophan (MESH:D014364), triazine (MESH:D014227), A (MESH:D001151), trimethoprim (MESH:D014295), CL (MESH:D002713), rosiglitazone (MESH:D000077154), D- or L-tryptophan (-), silica (MESH:D012822), acetohexamide (MESH:D000092), lofexidine (MESH:C025655), L-thyroxine (MESH:D013974), buspirone (MESH:D002065), sertraline (MESH:D020280), 4-methylumbelliferyl alpha-D-galactopyranoside (MESH:C026845), nortriptyline (MESH:D009661), biotin (MESH:D001710)
- **Species:** Equus caballus (domestic horse, species) [taxon 9796], Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A for A, A with L

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12883148/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12883148/full.md

## References

178 references — full list in the complete paper: https://tomesphere.com/paper/PMC12883148/full.md

---
Source: https://tomesphere.com/paper/PMC12883148